Predicting first-episode psychosis patients who will never relapse over 10 years

Abstract Background Although relapse in psychosis is common, a small proportion of patients will not relapse in the long term. We examined the proportion and predictors of patients who never relapsed in the 10 years following complete resolution of positive symptoms from their first psychotic episode. Method Patients who previously enrolled in a 12-month randomized controlled trial on medication discontinuation and relapse following first-episode psychosis (FEP) were followed up after 10 years. Relapse of positive symptoms was operationalized as a change from a Clinical Global Impression scale positive score of <3 for at least 3 consecutive months to a score of ⩾3 (mild or more severe). Baseline predictors included basic demographics, premorbid functioning, symptoms, functioning, and neurocognitive functioning. Results Out of 178 first-episode patients, 37 (21%) never relapsed during the 10-year period. Univariate predictors (p ⩽ 0.1) of patients who never relapsed included a duration of untreated psychosis (DUP) ⩽30 days, diagnosed with non-schizophrenia spectrum disorders, having less severe negative symptoms, and performing better in logical memory immediate recall and verbal fluency tests. A multivariate logistic regression analysis further suggested that the absence of any relapsing episodes was significantly related to better short-term verbal memory, shorter DUP, and non-schizophrenia spectrum disorders. Conclusions Treatment delay and neurocognitive function are potentially modifiable predictors of good long-term prognosis in FEP. These predictors are informative as they can be incorporated into an optimum risk prediction model in the future, which would help with clinical decision making regarding maintenance treatment in FEP.

[1]  Peter B. Jones,et al.  Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial. , 2018, The lancet. Psychiatry.

[2]  P. Sham,et al.  Visual working memory deterioration preceding relapse in psychosis , 2016, Psychological Medicine.

[3]  H. Möller,et al.  Predictors for symptom re-exacerbation after targeted stepwise drug discontinuation in first-episode schizophrenia Results of the first-episode study within the German research network on schizophrenia , 2016, Schizophrenia Research.

[4]  J. O. Johannessen,et al.  Neurocognition and Duration of Psychosis: A 10-year Follow-up of First-Episode Patients. , 2015, Schizophrenia bulletin.

[5]  N. Andreasen Scale for the Assessment of Negative Symptoms , 2014 .

[6]  H. So,et al.  10-year outcome study of an early intervention program for psychosis compared with standard care service , 2014, Psychological Medicine.

[7]  P. Sham,et al.  Prospective relationship between duration of untreated psychosis and 13-year clinical outcome: A first-episode psychosis study , 2014, Schizophrenia Research.

[8]  D. Streiner,et al.  Risk of symptom recurrence with medication discontinuation in first-episode psychosis: A systematic review , 2014, Schizophrenia Research.

[9]  W. Honer,et al.  Predicting 1-year risk for relapse in patients who have discontinued or continued quetiapine after remission from first-episode psychosis , 2013, Schizophrenia Research.

[10]  D. Wiersma,et al.  Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. , 2013, JAMA psychiatry.

[11]  Peter B. Jones,et al.  Cross-national clinical and functional remission rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) study , 2011, British Journal of Psychiatry.

[12]  A. Yung,et al.  Prediction of a single psychotic episode: A 7.5-year, prospective study in first-episode psychosis , 2011, Schizophrenia Research.

[13]  W. Honer,et al.  Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial , 2010, BMJ : British Medical Journal.

[14]  S. Lewis,et al.  Predictors of 10-year outcome of first-episode psychosis , 2009, Psychological Medicine.

[15]  H. Möller,et al.  Neuropsychological impairments predict the clinical course in schizophrenia , 2008, European Archives of Psychiatry and Clinical Neuroscience.

[16]  D. Wiersma,et al.  Guided Discontinuation Versus Maintenance Treatment in Remitted First-Episode Psychosis: Relapse Rates and Functional Outcome , 2007 .

[17]  J. O. Johannessen,et al.  The course of neurocognitive functioning in first-episode psychosis and its relation to premorbid adjustment, duration of untreated psychosis, and relapse , 2007, Schizophrenia Research.

[18]  E. Chen,et al.  A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients , 2005, Schizophrenia Research.

[19]  K. Chung,et al.  The impact of family experience on the duration of untreated psychosis (DUP) in Hong Kong , 2005, Social Psychiatry and Psychiatric Epidemiology.

[20]  H. Möller,et al.  The impact of the duration of untreated psychosis prior to first psychiatric admission on the 15-year outcome in schizophrenia , 2003, Schizophrenia Research.

[21]  Peter B. Jones,et al.  The Clinical Global Impression–Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia , 2003, Acta psychiatrica Scandinavica. Supplementum.

[22]  Zhening Liu,et al.  The Chinese-bilingual SCID-I/P Project: Stage 1 — Reliability for Mood Disorders and Schizophrenia , 2003 .

[23]  D. Linszen,et al.  Early intervention and a five year follow up in young adults with a short duration of untreated psychosis: ethical implications , 2001, Schizophrenia Research.

[24]  J. O. Johannessen,et al.  Premorbid functioning versus duration of untreated psychosis in 1 year outcome in first-episode psychosis , 2000, Schizophrenia Research.

[25]  J. Os,et al.  Medication adherence in psychosis: predictors and impact on outcome.A 2‐year follow‐up of first‐admitted subjects , 2000, Acta psychiatrica Scandinavica.

[26]  J. Lieberman,et al.  Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. , 1999, Archives of general psychiatry.

[27]  W. Eaton,et al.  Outcome of Schizophrenia: The Madras Longitudinal Study , 1996, The Australian and New Zealand journal of psychiatry.

[28]  N C Andreasen,et al.  Awareness of illness in schizophrenia and schizoaffective and mood disorders. , 1994, Archives of general psychiatry.

[29]  H. Goldman,et al.  Revising axis V for DSM-IV: a review of measures of social functioning. , 1992, The American journal of psychiatry.

[30]  A. Riecher-Rössler,et al.  IRAOS: an instrument for the assessment of onset and early course of schizophrenia , 1992, Schizophrenia Research.

[31]  Jean Addington,et al.  Reliability and validity of a depression rating scale for schizophrenics , 1991, Schizophrenia Research.

[32]  N. Andreasen The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and Theoretical Foundations , 1989, British Journal of Psychiatry.

[33]  T. Barnes A Rating Scale for Drug-Induced Akathisia , 1989, British Journal of Psychiatry.

[34]  U. Ahlfors,et al.  The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients , 1987, Acta psychiatrica Scandinavica. Supplementum.

[35]  P. Grahame The Northwick Park Study of First Episodes of Schizophrenia , 1986, British Journal of Psychiatry.

[36]  T. Crow,et al.  II. A Randomised Controlled Trial of Prophylactic Neuroleptic Treatment , 1986, British Journal of Psychiatry.

[37]  W T Carpenter,et al.  The prediction of outcome in schizophrenia. I. Characteristics of outcome. , 1972, Archives of general psychiatry.

[38]  G. Simpson,et al.  A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.

[39]  P. Bebbington Editing Social Psychiatry and Psychiatric Epidemiology , 2003, Epidemiologia e Psichiatria Sociale.

[40]  A. Schene,et al.  Predictors of the early 5-year course of schizophrenia: a path analysis. , 2005, Schizophrenia bulletin.

[41]  N. Smeeton,et al.  The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. , 1989, Psychological medicine. Monograph supplement.

[42]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[43]  R. Wyatt,et al.  Measurement of premorbid adjustment in chronic schizophrenia. , 1982, Schizophrenia bulletin.